PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with limited treatment options.
• Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD-L1) offer therapeutic promise.
• The function of intracellular PD-L1 in GBM pathogenesis is not well understood.

Purpose of the Study:

• To investigate the oncogenic role of intracellular PD-L1 in GBM.
• To elucidate the molecular mechanisms by which PD-L1 influences GBM cell behavior.
• To explore the therapeutic potential of targeting intracellular PD-L1 in GBM.

Main Methods:

• RNA-sequencing to analyze gene expression changes in GBM cells with altered PD-L1 levels.
• In vitro and in vivo experiments using GBM cell lines and orthotopic rodent models to assess proliferation, migration, and invasion.
• Co-immunoprecipitation to identify protein-protein interactions between PD-L1 and Ras.
• Western blotting and pathway analysis to investigate signaling cascades (MEK/Erk, PI3K/Akt) and epithelial-mesenchymal transition (EMT).

Main Results:

• PD-L1 overexpression significantly promoted GBM cell proliferation, migration, and invasion in vitro and in vivo.
• PD-L1 activated the epithelial-mesenchymal transition (EMT) via the MEK/Erk pathway, independent of PI3K/Akt.
• Intracellular PD-L1 directly binds to H-Ras, leading to Ras/Erk signaling activation and subsequent EMT.
• PD-L1 knockdown inhibited GBM development and invasion in preclinical models.

Conclusions:

• Intracellular PD-L1 acts as an oncogene in GBM by activating Ras/Erk/EMT signaling, contributing to tumor malignancy and aggressiveness.
• Targeting the intracellular interaction of PD-L1 and Ras presents a novel therapeutic strategy for GBM.
• Understanding PD-L1's intracellular functions is crucial for optimizing immune therapy efficacy in GBM and other cancers.